CD8A and neoplasm: It is known that the CD8+ T lymphocytes, which have the NK-activating receptor NKG2D on their surface, acquire an NK-like activity and the ability to kill the HLA-negative tumor cells after a prolonged incubation with the IL-15 or IL-2 cytokines [7–9].